

IL-1RA Catalog # PVGS1004

Product Information

Primary Accession Species	<u>P18510-1</u> Human
Sequence	Arg26-Glu177
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level Biological Activity	Measured by its ability to inhibit IL-1 beta induced NF-kB signaling in 293-IL1 Res cells. The ED_{50} for this effect is 13.2 ng/mL.
Expression System	E. coli
Theoretical Molecular Weight	17.3 kDa
Formulation Reconstitution	Lyophilized from a 0.2 Im filtered solution of PBS, pH 7.4. It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 Ig/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

Additional Information

Target BackgroundInterleukin-1 receptor antagonist (IL-1ra) is a member of the IL-1 family.
Endogenous IL-1ra is produced in numerous animal disease models as well as
in human autoimmune and chronic inflammatory diseases. It binds to IL-1
receptors in competition with IL-1, but does not elicit intracellular response
from this binding. Its role in counteracting the proinflammatory effects of IL-1
is being studied by numerous research groups. IL-4 and IL-13 have been
shown to amplify the stimulatory effect of IL1-beta on the production of
soluble and intracellular forms of IL1-ra. The regulated expression of IL1ra in
various cell types has been shown to be influenced by cytokines. In synovial
fibroblasts the synthesis of IL-1ra is markedly enhanced by IL-1, TNF-alpha, or
PDGF.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.